Targeting menin: a promising therapeutic strategy for susceptible acute leukemia subtypes

Two recent studies published in Nature focused on the clinical efficacy of the menin inhibitor revumenib (SNDX-5613) in KMT2A (histone-lysine N-methyltransferase 2A)-rearranged or NPM1 (Nucleophosmin1)-mutant acute myeloid leukemia.1,2 These studies indicate that menin inhibition and its acquired re...

Full description

Saved in:
Bibliographic Details
Main Author: Di Fazio, Pietro
Format: Article
Published: Philipps-Universität Marburg 2024
Online Access:PDF Full Text
Tags: Add Tag
No Tags, Be the first to tag this record!